No treatment with any other type of investigational agent =<  weeks before pre-registration
No treatment with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =<  days before study registration; no treatment with nitrosourea or mitomycin =<  days before study registration; for GIST, tyrosine kinase inhibitor can be continued for up to  days prior to initiation of study treatment
No treatment with immunotherapy =<  days before re-registration; no treatment with biologic therapy, chemotherapy, investigational agent for malignancy, or radiation =<  days before re-registration; no treatment with nitrosourea or mitomycin =<  days before re-registration
No treatment with biological therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =<  days before study registration; no treatment with nitrosourea or mitomycin =<  days before study registration
No investigational agent within  days prior to registration
No investigational therapy within  days prior to registration
Patients must not have any anticancer therapy or investigational agent within  days prior to step  registration
Treatment with any investigational agent within  days prior to registration for protocol therapy
Other investigational treatment during or within  days before starting study registration
Subjects on treatment with chemotherapy or any investigational therapeutic agent will need to discontinue therapy  weeks prior to registration (wash out period)
Treatment with any therapeutic investigational agent within  days prior to study registration.
Patients must not have received treatment with any chemotherapy, immunotherapy, radiotherapy or an investigational agent for malignancy within the  days preceding study registration; patients may not have received treatment with nitrosoureas or mitomycin within the  days prior to study registration; patients may not have received treatment with a small molecule targeted agent (including off-label or investigational use) within  days preceding study registration, provided this represents at least  half-lives for that agent; toxic effects from any prior therapy (except alopecia) must have resolved to grade  or less according to National Cancer Institute (NCI) CTCAE version (v). or to the patients baseline by the time of registration
Treatment with an investigational agent within  weeks of registration
Treatment with any investigational agent within  days prior to being registered for protocol therapy
No treatment with any investigational agent for any medical condition within  days prior to being registered for protocol therapy
Treatment with any investigational agent or on an interventional clinical trial within  days prior to treatment on protocol
Treatment with any investigational agent or on an interventional clinical trial within  days prior to registration
No treatment with any investigational agent within  days prior to being registered for protocol therapy
No treatment with any investigational agent within  days prior to registration for protocol therapy
Any other investigational agent or used an investigational device within  days prior to day  of protocol therapy
Treatment with any investigational agent within  days prior to registration for protocol therapy
No treatment with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =<  days before study registration; no treatment with nitrosourea or mitomycin =<  days before study registration
Treatment with any investigational agent within  days prior to registration for protocol therapy
Treatment with any investigational agent within  days prior to being registered for protocol therapy
Prior treatment with any other agent that may affect M-protein =<  days prior to registration
Use of an investigational agent within the previous  days of study registration
Treatment with any other investigational agent within  days prior to registration. Subjects must not be treated with any other investigational agent while on protocol specified therapy.
No treatment with any investigational agent within  days prior to registration for protocol therapy.
Investigational agent within  days prior to day  of protocol therapy
Treatment with any investigational agent within  days prior to registration for protocol therapy
Subjects must have received their last dose of investigational or biologic agent >=  days prior to study registration\r\n* In the event that a subject has received an investigational or biologic agent and has experienced >= grade  myelosuppression, then at least three () weeks must have elapsed prior to registration\r\n* If the investigational or biologic agent has a prolonged half-life (>=  days) then at least three () weeks must have elapsed prior to registration
No treatment with any investigational agent within  days prior to study registration.
Treatment with any investigational agent within  days prior to being registered for protocol therapy
Treatment with any investigational agent within  days prior to registration.
Any investigational agent is acceptable if administered >=  days before registration
No treatment with any investigational agent within  days prior to registration for protocol therapy. NOTE: If treated with investigational agent within  days prior to registration, AE must be resolved back to baseline.
Treatment with any investigational agent within  days prior to registration for protocol therapy
Administration of any investigational agent =<  days prior to pre-registration
